Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814851 | 0.87 | HSD11B1 (0.50) | HSD11B1ALDH1A1GRIN1GRIN2BHPGD | |
| SCHEMBL30085323 | 0.84 | KCNJ1 (0.40) | KCNJ1KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL20470405 | 0.84 | KCNJ1 (0.40) | KCNJ1KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL15466330 | 0.84 | KCNJ1 (0.40) | KCNJ1KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16311933 | 0.82 | ALDH1A1 (0.41) | KCNJ1KCNH2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL22481395 | 0.81 | ALDH1A1 (0.43) | KCNJ1KCNH2HSD11B1KDM4EALDH1A1 | |
| SCHEMBL22481142 | 0.80 | HIF1A (0.47) | KCNJ1KCNH2 | |
| SCHEMBL22481210 | 0.80 | HIF1A (0.47) | KCNJ1KCNH2 | |
| SCHEMBL28686674 | 0.80 | HIF1A (0.47) | KCNJ1KCNH2 | |
| SCHEMBL19003579 | 0.78 | KDM4E (0.40) | KCNJ1KCNH2KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | KCNJ1 24/4885KCNH2 48/4885HSD11B1 4462/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | KCNJ1 24/4885KCNH2 48/4885HSD11B1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.